Navigation Links
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Date:2/19/2013

assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.  Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions.  Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary
'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... LAS VEGAS , March 27, 2015 Zimmer ... more efficient external fixation system for trauma patients. ... the XtraFix ® External Fixation System from ... design technology and materials.   The XtraFix ... and clamps from the external fixation process, resulting in saved ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... Transdermal System CIII 20 mcg/hour provided significantly ... compared to Butrans 5 mcg/hour when used in opioid-experienced ... according to a pivotal Phase 3 clinical study published ... of Pain . (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262) ...
... SILVER SPRING, Md., Sept. 23, 2011 The U.S. ... treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a ... kidney (renal) failure and is also associated with increased ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Atypical HUS accounts ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 "Necrorun" was ... which takes a look at the latest and coolest ... Joe Troohey, the host of NewsWatch and technology expert, ... this is an entertaining endless runner game with knights, ... game was released in 2009, according to Eurogamer. The ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Jan. 3 Continuing its role as ... organizations, the,American Association of Preferred Provider Organizations ... Care Administrators Association,(HCAA) that will significantly enhance ... consolidation and increased consumerism continue to fuel,further ...
... and Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, ... have no early symptoms and do not notice as their peripheral,vision ... the,three million Americans with the disease are unaware of their condition.,January ...
... In an era of expanding competition,from generics, expiring ... in new drug discoveries, there is very little ... report by Kalorama Information entitled Drug,Pricing and Reimbursement ... companies the information they need to,reevaluate their pricing ...
... 3 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that a registration,statement covering the ... effective by the Securities and Exchange Commission on ... informational purposes only, and does not,represent a solicitation ...
... finds one-hour session produces as much carbon monoxide as a ... A leisurely hour of puffs from a hookah -- a ... -- packs the same carbon monoxide punch as a pack-a-day ... looks at a single toxic gas, making it impossible to ...
... Emory University have developed a novel anti-tumor compound that represents ... points" for cancer cells. , The results of research on ... of Cancer Research. The article is highlighted on the cover. ... human patients with solid tumors in 2007. , The idea ...
Cached Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 3Health News:Novel anticancer strategy moves from laboratory to clinic 2Health News:Novel anticancer strategy moves from laboratory to clinic 3
... EVLT, the #1 physician choice in ... advantages to remedying superficial vein reflux. EVLT ... to surgical vein stripping that effectively and ... laser fiber to occlude the vein. The ...
... Aculens 186 UV combines the latest technology ... measurement of ultra violet transmission and auto ... is also programmed to network with the ... Instruments, today, or in the future. , ...
Inquire...
...
Medicine Products: